Stock APLM APOLLOMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Apollomics, Inc.

Equities

APLM

KYG0411D1079

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
0.4025 USD -4.14% Intraday chart for Apollomics, Inc. -5.52% -58.29%
Apr. 25 Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene CI
Apr. 05 Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Apollomics : April 2024 Corporate Presentation
PU
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene
CI
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
GL
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
GL
Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer
CI
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
GL
EF Hutton Cuts Price Target on Apollomics to $6.50 From $11, Maintains Buy Rating
MT
HC Wainwright Adjusts Apollomics' Price Target to $5 From $17, Maintains Buy Rating
MT
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
GL
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
AQ
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
GL
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
AQ
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
GL
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
AQ
Apollomics, Inc. Appoints Matthew Plunkett as Chief Financial Officer
CI
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GL
Apollomics Gets Nasdaq Noncompliance Notice
MT
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
GL
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLM Stock
  4. News Apollomics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW